Tailoring the dosage of Botox to help treat involuntary movements improves the effect on cerebral palsy patients. That’s according to the findings of new study.
Researchers from the University of Bari, Italy, published their report in the journal Toxins after undertaking tests to gauge the effectiveness of toxin type A (BTX-A), popularly known as Botox, on cerebral palsy patients.
As it helps to reduce rigidity in muscles, Botox has previously been prescribed to help prevent twitching, but only in measured standard or high doses. The study looked to see whether a more individual approach to dosage offered improved the results.
Using 120 cerebral palsy patients displaying involuntary movements, the study split them into three groups. The first group of 30 patients received a dosage of up to 400 units; the second group of 40 received 400-700 units; and the third group of 50 received 700-1,000 units.
The Botox treatment was combined with rehabilitation exercises and using two scales – the functional independence measure and the MyotonPRO – the patients were assessed.
The results found there to be no significant improvements to the involuntary movements of those in the first group. However, when 10 of those patients were moved into the second group for their final injection, their symptoms improved.
The same occurred for eight patients in the second group, who underwent no discernible improvements, when they were moved into the third group. And all of the patients in the third group showed improvements to their involuntary movements.
The study demonstrated that doses ranging from 400 to 1,000 units displayed a degree of improvement and that tailoring the dosage on a patient by patient basis was key to achieving this.